The results of the meta-analysis indicated that GLP-1 receptor agonists reduced the risk of fatal or non-fatal stroke compared with the placebo (RR: 0.85; 95% CI: 0.77 – 0.94; P = 0.001). This evidence concerns the gene GLP1R and Stroke.